München
22.06.26 | 08:09
0,059 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.05. | Isofol Medical AB: Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026 | 392 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) (the "Company") held its annual general meeting (the "AGM") today. The following resolutions, in principle, were... ► Artikel lesen | |
| 19.05. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - March 2026 | 132 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - March 2026 is now... ► Artikel lesen | |
| 15.04. | Isofol Medical AB: Isofol optimizes the design of its phase Ib/II study following new regulatory approval | 410 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, April 15, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority BfArM has approved an optimized design for the company's... ► Artikel lesen | |
| 18.03. | Isofol Medical AB: Isofol secures license rights for arfolitixorin in autism | 1.186 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, March 18, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded its global exclusive license agreement for arfolitixorin to also... ► Artikel lesen | |
| 11.03. | Isofol Medical AB: Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise | 324 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 11 March 2026 - Isofol Medical AB ("Isofol" or the "Company") announces today that the Company has received a top guarantee commitment from existing shareholder Solasia Pharma K.K.... ► Artikel lesen | |
| 24.02. | Isofol Medical AB: Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin | 349 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 24, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company's ongoing phase Ib/II clinical study of arfolitixorin, which is initially... ► Artikel lesen | |
| 18.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2025 | 180 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 18, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's year-end report for January - December 2025... ► Artikel lesen | |
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 13.11.25 | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | 335 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| 12.11.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2025 | 247 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January-September 2025... ► Artikel lesen | |
| 30.09.25 | Isofol Medical AB: Isofol's clinical study with arfolitixorin reaches another important milestone | 443 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 30, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed the second dose level in the dose escalating... ► Artikel lesen | |
| 26.09.25 | Isofol Medical AB: Isofol completes transfer of shares to Solasia Pharma following a successful rights issue | 319 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the transfer of the shares subscribed by the Japanese collaboration partner Solasia... ► Artikel lesen | |
| 26.08.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2025 | 252 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2025 is now available, in Swedish, on the... ► Artikel lesen | |
| 16.07.25 | Isofol Medical AB: Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin | 343 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 16, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed a pre-IND meeting with the U.S. Food and Drug Administration... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,300 | 0,00 % | ALARMSTUFE ROT bei Valneva: Warum erfahrene Anleger heute die Reißleine ziehen - So reagieren erfahrene Anleger jetzt | ||
| INTELLIA THERAPEUTICS | 14,040 | +5,09 % | Handel mit Optionen auf Intellia Therapeutics steigt sprunghaft an | ||
| SIRONA BIOCHEM | 0,037 | +5,80 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,157 | -4,93 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,916 | -1,08 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| ATAIBECKLEY | 3,600 | +1,69 % | Why AtaiBeckley (ATAI) Is Building Its Valuation Case Around BPL-003's Phase 3 Readiness | ||
| BIOMERIEUX | 67,20 | -2,18 % | Dividendenbekanntmachungen (09.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMEREN CORPORATION US0236081024 0,75 USD 0,6501 EUR AMUNDI SA FR0004125920 - 4,25 EUR BECTON DICKINSON AND COMPANY US0758871091 1... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 0,710 | -6,33 % | Bio Green Med Solution, Inc. - 8-K, Current Report | ||
| GENUS | 25,000 | 0,00 % | Genus PLC - Holding(s) in Company | ||
| ANAPTYSBIO | 50,72 | +1,44 % | ANAPTYSBIO, INC - 8-K, Current Report | ||
| MEIRAGTX | 10,100 | +1,00 % | MeiraGTx Reports First Quarter 2026 Financial and Operational Results | Received FDA Breakthrough Therapy Designation for AAV2-hAQP1Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomiaEntered... ► Artikel lesen | |
| ABIONYX PHARMA | 2,210 | +0,91 % | ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M | Capital increase fully subscribed for a total amount of EUR 18.7 M through the issuance of 7,056,416 New Shares at a subscription price of EUR 2.65 per share Drawdown of the First Tranche... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 2,020 | 0,00 % | XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from Nasdaq | RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter")... ► Artikel lesen | |
| AKESO | 9,236 | -4,11 % | Akeso, Inc.: Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026 | HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind... ► Artikel lesen | |
| MAAT PHARMA | 2,730 | -3,87 % | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
11.06.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen |
Das Unternehmen ISOFOL MEDICAL AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,059 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.